{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:07:44Z","timestamp":1779887264882,"version":"3.53.1"},"reference-count":37,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Generalized myasthenia gravis (gMG) severely impacts activities of daily living. Productivity losses and the need for care can impact household finances and consequently government public accounts. This study adopts a governmental perspective framework to assess the fiscal consequences of treating gMG that is inadequately controlled by standard therapy, beyond healthcare costs. Savings in tax revenue loss and benefit payments are considered.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To value the fiscal consequences of treating adults with acetylcholine receptor\u2013antibody positive (AChR-Ab+) gMG with efgartigimod vs current treatments. The lifetime impact on people living with gMG and their caregivers is considered from the perspective of Canada\u2019s public accounts.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A lifetime Markov cohort simulation following adults with gMG according to their Activities of Daily Living (MG-ADL) score was linked to labor and fiscal stages of both patients and care-\n                  <\/jats:p>\n                  <jats:p>givers. Based on the MyRealWorld MG study, MG-ADL scores defined the labor market characteristics of both individuals with gMG and their caregivers. National statistics data on sex- and age-specific labor outcomes were used to model patients with minimal symptoms. Benefit payments and tax revenue losses attributable to gMG were estimated and valued according to national official sources. Public healthcare costs were included. The difference between efgartigimod and current treatments was assessed by discounted lifetime incremental fiscal consequences. Sensitivity analyses were applied to the fiscal parameters.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Without active treatments, the lifetime fiscal burden associated with individuals with gMG and their caregivers was estimated at CAD$1.24 million in government expenditures. Compared with the current weighted bundle of treatments in Canada, efgartigimod was estimated to save CAD$458\u2009754 per treated adult. Results were sensitive to the distribution of the bundle of treatments.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:<\/jats:bold>\n                    Beyond healthcare costs, gMG severely impacts productivity and governmental accounts. Decision-makers should be provided evidence of fiscal consequences when assessing healthcare technologies. The public sector in Canada was estimated to have a return of CAD$1.58 per every CAD$1 spent on efgartigimod for people with gMG compared with the current bundle of treatments.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Improving health outcomes and reducing the need for informal caregivers benefits those affected by gMG and governmental accounts.\n                  <\/jats:p>","DOI":"10.36469\/001c.157709","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:31:53Z","timestamp":1773243113000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":1,"title":["The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis"],"prefix":"10.36469","volume":"13","author":[{"given":"Ana Teresa","family":"Paquete","sequence":"first","affiliation":[{"name":"Global Market Access Solutions LLC, Mooresville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Global Market Access Solutions LLC, Mooresville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Qi","sequence":"additional","affiliation":[{"name":"argenx US Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Katzberg","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Raza","sequence":"additional","affiliation":[{"name":"argenx UK Ltd, Mylton Keynes, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kassardjian","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada","department":["epartment of Neurology, Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaeem A.","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada","department":["Division of Neurology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kaprielian","sequence":"additional","affiliation":[{"name":"argenx, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Locklin","sequence":"additional","affiliation":[{"name":"argenx, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"argenx US Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Kotsopoulos","sequence":"additional","affiliation":[{"name":"Global Market Access Solutions LLC, Mooresville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","article-title":"CADTH Reimbursement Review: Efgartigimod Alfa (Vyvgart)","author":"CADTH","DOI":"10.51731\/cjht.2024.811"},{"issue":"4","key":"ref2","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"F. Sacca","year":"2023","journal-title":"J Neurol"},{"key":"ref3","article-title":"CADTH Drug Reimbursement Review Pharmacoeconomic Report: Eculizumab (Soliris)","author":"CADTH","year":"2020"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.868","article-title":"CADTH Reimbursement Recommendation: Efgartigimod Alfa (Vyvgart)","volume":"4","author":"CADTH","year":"2024"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"S. Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"issue":"10","key":"ref6","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","article-title":"People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies","volume":"40","author":"S. Dewilde","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12325-023-02704-w","article-title":"The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population","volume":"41","author":"S. Dewilde","year":"2024","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1538789","article-title":"A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity","volume":"13","author":"S. Dewilde","year":"2025","journal-title":"Front Public Health"},{"key":"ref9","article-title":"Data on file. Market shares. 2024"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2025.10449","article-title":"Cost-effectiveness analysis of efgartigimod vs chronic immunoglobulin for the treatment of myasthenia gravis in Canada","author":"Z. A. Siddiqi","year":"2025","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"ref11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","article-title":"Employment in myasthenia gravis: a systematic literature review and meta-analysis","volume":"54","author":"E. Guastafierro","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13023-025-03842-w","article-title":"Caregiving burden among caregivers of people with myasthenia gravis","volume":"20","author":"S. Dewilde","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","article-title":"Canada's Cost-Benefit Analysis Guide for Regulatory Proposals","author":"Government of Canada","year":"2024"},{"key":"ref14","article-title":"Procedures for Reimbursement Reviews","year":"2024"},{"key":"ref15","article-title":"Table 14-10-0064-01 Employee Wages by Industry, Annual","author":"Statistics Canada","year":"2024"},{"key":"ref16","article-title":"Table 18-10-0005-01 Consumer Price Index, annual average, not seasonally adjusted","author":"Statistics Canada","year":"2024"},{"key":"ref17","article-title":"Table 14-10-0327-01 Labour force characteristics by sex and detailed age group, annual","author":"Statistics Canada","year":"2024","journal-title":"annual"},{"key":"ref18","article-title":"Table 11-10-0239-01 Income of individuals by age group, sex and income source, Canada, provinces and selected census metropolitan areas","author":"Statistics Canada","year":"2023"},{"key":"ref19","article-title":"Table 36-10-0480-01 Labour productivity and related measures by business sector industry and by non-commercial activity consistent with the industry accounts","author":"Statistics Canada","year":"2024"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"e068104","DOI":"10.1136\/bmjopen-2022-068104","article-title":"Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)","volume":"13","author":"S. Berrih-Aknin","year":"2023","journal-title":"BMJ Open"},{"key":"ref21","article-title":"Productivity losses for MG patients and their caregivers\u2013association with disease severity","author":"S. Jacob","year":"2024"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","article-title":"Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"K. Schepelmann","year":"2010","journal-title":"J Neurol"},{"key":"ref23","article-title":"Taxing Wages\u2013Canada 2023","author":"OECD"},{"key":"ref24","article-title":"Tax on Goods and Services, as a Percentage of Gross Domestic Product","author":"OECD","year":"2024"},{"key":"ref25","article-title":"Tax Revenue (Indicator)","author":"OECD","year":"2024"},{"key":"ref26","article-title":"Employment Insurance benefits and leave","author":"Government of Canada"},{"key":"ref27","article-title":"Table 13-10-0358-01 Canada and Quebec Pension Plan Benefits of Adults with and without Disabilities","author":"Statistics Canada","year":"2015"},{"key":"ref28","article-title":"Old age security pension","author":"Government of Canada"},{"key":"ref29","article-title":"Caregiving benefits","author":"Government of Canada"},{"key":"ref30","article-title":"Data on file. MyRealWorld MG. 2022"},{"issue":"7","key":"ref31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"J. F., Jr. Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071130","article-title":"Evaluation of the quality of life of patients with myasthenia gravis in Greece","volume":"13","author":"A. Aggelina","year":"2023","journal-title":"J Pers Med"},{"issue":"7","key":"ref33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"S. Blum","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"A. Breiner","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"ref35","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.jval.2023.03.704","article-title":"EE403 Direct and indirect costs among employed patients with myasthenia gravis in Sweden","volume":"26","author":"Q. Cai","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"ref36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jval.2016.11.018","article-title":"The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework","volume":"20","author":"M. P. Connolly","year":"2017","journal-title":"Value Health"},{"key":"ref37","article-title":"Dame Carol Black's review of the health of Britain's working age population: working for a healthier tomorrow","author":"C. Black","year":"2008"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/157709-the-fiscal-consequences-for-the-canadian-government-of-efgartigimod-in-the-treatment-of-generalized-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:35:47Z","timestamp":1779885347000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/157709-the-fiscal-consequences-for-the-canadian-government-of-efgartigimod-in-the-treatment-of-generalized-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.157709","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}